NASDAQ:AMRS - Amyris Stock Price, Price Target & More

Get Started

$5.03 -0.15 (-2.90 %)

(As of 05/27/2018 06:10 AM ET)

Previous Close$5.03

Today's Range$4.8966 - $5.16

52-Week Range$1.86 - $7.30

Volume670,352 shs

Average Volume785,962 shs

Market Capitalization$252.39 million

P/E RatioN/A

Dividend YieldN/A

Beta0.15

About Amyris (NASDAQ:AMRS)

Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Industrial organic chemicals

Sub-IndustryOil & Gas Refining & Marketing

SectorBasic Materials

SymbolNASDAQ:AMRS

CUSIP03236M10

Webwww.amyris.com

Phone510-450-0761

Debt

Debt-to-Equity Ratio-0.35

Current Ratio0.67

Quick Ratio0.93

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$143.45 million

Price / Sales1.76

Cash FlowN/A

Price / CashN/A

Book Value($5.80) per share

Price / Book-0.87

Profitability

EPS (Most Recent Fiscal Year)($3.05)

Net Income$-72,320,000.00

Net Margins-85.70%

Return on EquityN/A

Return on Assets-125.68%

Miscellaneous

Employees414

Outstanding Shares50,180,000

Amyris (NASDAQ:AMRS) Frequently Asked Questions

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

When did Amyris' stock split? How did Amyris' stock split work?

Amyris shares reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

How were Amyris' earnings last quarter?

Amyris Inc (NASDAQ:AMRS) issued its quarterly earnings data on Monday, May, 14th. The biotechnology company reported ($1.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $1.31. The biotechnology company earned $23 million during the quarter, compared to the consensus estimate of $24.12 million. The business's revenue was up 77.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.13) earnings per share. View Amyris' Earnings History.

When is Amyris' next earnings date?

Amyris is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Amyris.

What price target have analysts set for AMRS?

3 Wall Street analysts have issued 12 month target prices for Amyris' shares. Their forecasts range from $4.00 to $15.00. On average, they expect Amyris' share price to reach $9.6667 in the next year. View Analyst Ratings for Amyris.

Who are some of Amyris' key competitors?

Some companies that are related to Amyris include Green Plains (GPRE), Codexis (CDXS), Westlake Chemical (WLKP), Renewable Energy Group (REGI), FutureFuel (FF), Green Plains Partners (GPP), REX American Resources (REX), Sino United Worldwide Consolidated (SUIC), Pacific Ethanol (PEIX), Tantech (TANH), China Insonline (WAYS), Aemetis (AMTX), CTD (CTDH), Gevo (GEVO) and OriginClear (OCLN).

Who are Amyris' key executives?

Amyris' management team includes the folowing people:

Mr. John G. Melo, Pres, CEO & Director (Age 52)
Dr. Joel R. Cherry, Pres of R&D (Age 57)
Ms. Kathleen Valiasek, Chief Financial Officer (Age 54)
Mr. Eduardo Alvarez, Chief Operating Officer (Age 54)
Ms. Tina F. Maloney, Chief Accounting Officer (Age 55)

Has Amyris been receiving favorable news coverage?

Press coverage about AMRS stock has trended somewhat positive on Sunday, Accern reports. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amyris earned a media sentiment score of 0.04 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 45.99 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Amyris' major shareholders?

Amyris' stock is owned by many different of institutional and retail investors. Top institutional shareholders include TEMASEK HOLDINGS (PRIVATE) LTD (8.90%), Millennium Management LLC (0.49%), Crown Advisors Management Inc. (0.20%), JPMorgan Chase & Co. (0.20%), KBC Group NV (0.13%) and BlackRock Inc. (0.11%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, John Melo, L John Doerr and Patrick Y Yang. View Institutional Ownership Trends for Amyris.

Which major investors are buying Amyris stock?

AMRS stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Crown Advisors Management Inc., JPMorgan Chase & Co., Barclays PLC, Tibra Equities Europe Ltd, B. Riley Financial Inc., Element Capital Management LLC and BlackRock Inc.. Company insiders that have bought Amyris stock in the last two years include L John Doerr and Patrick Y Yang. View Insider Buying and Selling for Amyris.

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $5.03.

How big of a company is Amyris?

Amyris has a market capitalization of $252.39 million and generates $143.45 million in revenue each year. The biotechnology company earns $-72,320,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis. Amyris employs 414 workers across the globe.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]

MarketBeat Community Rating for Amyris (AMRS)

Community Ranking:		2.2 out of 5 ( )
Outperform Votes:		168 (Vote Outperform)
Underperform Votes:		218 (Vote Underperform)
Total Votes:		386

MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Amyris (NASDAQ:AMRS) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for Amyris in the last 12 months. Their average twelve-month price target is $9.6667, suggesting that the stock has a possible upside of 92.18%. The high price target for AMRS is $15.00 and the low price target for AMRS is $4.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.67	2.67	2.67	2.67
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$9.6667	$9.6667	$9.00	$26.3333
Price Target Upside:	92.18% upside	44.49% upside	81.82% upside	730.70% upside

Amyris (NASDAQ:AMRS) Consensus Price Target History

Price Target History for Amyris (NASDAQ:AMRS)

Amyris (NASDAQ:AMRS) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/25/2018	HC Wainwright	Set Price Target	Buy	$15.00	Medium
5/20/2018	B. Riley	Set Price Target	Buy	$10.00	Low
11/29/2017	Cowen	Reiterated Rating	Hold	$4.00	High
1/11/2017	Rodman & Renshaw	Reiterated Rating	Buy	$60.00	N/A
9/28/2016	Singular Research	Reiterated Rating	Buy	$42.00	N/A

(Data available from 5/27/2016 forward)

Amyris (NASDAQ:AMRS) Earnings History and Estimates Chart

Earnings by Quarter for Amyris (NASDAQ:AMRS)

Amyris (NASDAQ:AMRS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.56)
2019 EPS Consensus Estimate: $0.16

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.38)	($0.38)	($0.38)
Q2 2018	1	($0.30)	($0.30)	($0.30)
Q3 2018	1	($0.11)	($0.11)	($0.11)
Q4 2018	1	$0.23	$0.23	$0.23
Q1 2019	1	($0.13)	($0.13)	($0.13)
Q2 2019	1	($0.03)	($0.03)	($0.03)
Q3 2019	1	$0.06	$0.06	$0.06
Q4 2019	1	$0.26	$0.26	$0.26

Amyris (NASDAQ AMRS) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/8/2018		($0.30)					N/A
5/14/2018	Q1 2018	($0.48)	($1.79)	$24.12 million	$23.00 million	View	Listen
3/15/2018	Q4 2017	$0.07	($0.17)	$68.14 million	$80.59 million	View	Listen
11/14/2017	Q3 2017	($0.77)	($0.81)	$36.30 million	$24.20 million	View	N/A
8/10/2017	Q2 2017	($1.06)	($1.41)	$23.68 million	$25.68 million	View	N/A
5/15/2017	Q1 2017	($1.35)	($1.95)	$32.30 million	$13.00 million	View	N/A
3/2/2017	Q4 2016	($0.75)	($1.50)	$38.72 million	$32.20 million	View	Listen
11/2/2016	Q316	($0.90)	($1.05)	$33.61 million	$26.50 million	View	N/A
8/4/2016	Q2	($1.80)	($0.90)	$15.23 million	$9.60 million	View	N/A
5/10/2016	Q1	($1.95)	($2.55)	$10.39 million	$8.80 million	View	Listen
3/9/2016	Q4	($1.50)	($2.40)	$32.44 million	$9.80 million	View	Listen
11/5/2015	Q315	($2.55)	($3.45)	$8.84 million	$8.60 million	View	N/A
8/6/2015	Q215	($4.65)	($7.95)	$15.66 million	$7.80 million	View	N/A
5/5/2015	Q115	($1.50)	($6.15)	$21.40 million	$7.90 million	View	N/A
2/24/2015	Q414	($3.00)	($12.60)	$20.12 million	$11.60 million	View	N/A
11/4/2014	Q314	($2.10)	($4.20)	$20.51 million	$16.34 million	View	N/A
8/7/2014	Q214	($5.55)	($5.25)	$12.36 million	$9.30 million	View	N/A
5/8/2014	Q114	($4.80)	($5.40)	$13.50 million	$17.90 million	View	N/A
2/25/2014	Q413	($3.60)	($3.90)	$18.66 million	$15.40 million	View	N/A
10/31/2013	Q313	($4.50)	($4.80)	$13.59 million	$7.00 million	View	N/A
8/8/2013	Q2 2013	($4.80)	($5.10)	$11.47 million	$10.80 million	View	N/A
4/30/2013	Q1 2013	($5.85)	($5.85)	$9.80 million	$7.87 million	View	N/A
2/19/2013	Q4 2012	($7.65)	($7.35)	$10.68 million	$5.90 million	View	N/A
11/6/2012	Q312	($9.45)	($3.30)	$10.49 million	$19.10 million	View	N/A
7/31/2012		($10.35)	($9.90)			View	N/A
5/8/2012		($11.40)	($28.20)			View	N/A
2/27/2012	Q4 2011	($12.74)	($19.51)			View	N/A
11/1/2011		($10.65)	($14.55)			View	N/A
8/2/2011		($9.45)	($14.25)			View	N/A
5/5/2011		($7.50)	($11.40)			View	N/A
2/28/2011		($7.35)	($7.65)			View	N/A
11/4/2010	Q3 2010		($57.74)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Amyris (NASDAQ:AMRS) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Amyris (NASDAQ AMRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.80%
Institutional Ownership Percentage: 23.95%

Insider Trading History for Amyris (NASDAQ:AMRS)

Institutional Ownership by Quarter for Amyris (NASDAQ:AMRS)

Amyris (NASDAQ AMRS) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/7/2018	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	95,162	$6.54	$622,359.48
1/16/2018	John Melo	Insider	Sell	10,776	$4.68	$50,431.68	83,172
5/19/2017	Patrick Y Yang	Director	Buy	300,000	$0.29	$87,000.00	153,000
4/20/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	652,513	$0.55	$358,882.15
4/18/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	1,636,930	$0.65	$1,064,004.50
3/30/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	184,535	$0.51	$94,112.85
3/29/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	417,990	$0.51	$213,174.90
3/27/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	129,059	$0.48	$61,948.32
3/23/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	165,428	$0.48	$79,405.44
3/21/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	223,073	$0.48	$107,075.04
3/20/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	88,382	$0.49	$43,307.18
3/17/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	339,908	$0.49	$166,554.92
3/15/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	270,374	$0.46	$124,372.04
3/13/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	346,429	$0.50	$173,214.50
3/9/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	520,925	$0.46	$239,625.50
3/7/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	852,224	$0.45	$383,500.80
3/3/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	868,589	$0.49	$425,608.61
3/1/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	377,823	$0.51	$192,689.73
2/27/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	287,706	$0.52	$149,607.12
2/23/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	529,747	$0.53	$280,765.91
2/21/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	287,528	$0.56	$161,015.68
2/16/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	390,918	$0.54	$211,095.72
2/10/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	429,198	$0.51	$218,890.98
2/8/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	288,765	$0.50	$144,382.50
1/12/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	29,502	$0.81	$23,896.62
1/11/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	451,806	$0.81	$365,962.86
1/9/2017	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	1,072,847	$0.81	$869,006.07
12/14/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	87,291	$0.80	$69,832.80
12/12/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	54,286	$0.80	$43,428.80
12/8/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	285,623	$0.81	$231,354.63
12/6/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	578,550	$0.81	$468,625.50
12/2/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	556,296	$0.84	$467,288.64
11/22/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	77,383	$0.80	$61,906.40
11/17/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	509,779	$0.81	$412,920.99
11/15/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	648,342	$0.81	$525,157.02
11/11/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	427,904	$0.81	$346,602.24
11/8/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	333,811	$0.82	$273,725.02
11/4/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	2,611,233	$0.89	$2,323,997.37
10/17/2016	(Mauritius) Pte Ltd Maxwell	Major Shareholder	Sell	2,300,000	$0.83	$1,909,000.00
6/14/2016	L John Doerr	Director	Buy	200,577	$1.04	$208,600.08	15,000
10/14/2015	Energies Nouvelles Activ Total	Director	Sell	80,052	$2.36	$188,922.72	64,178,185
6/5/2015	John Melo	CEO	Sell	61,276	$2.00	$122,552.00
5/12/2015	John Melo	CEO	Sell	65,575	$2.08	$136,396.00
5/15/2014	L John Doerr	Director	Buy	172,186	$3.02	$520,001.72	9,000
5/24/2013	John Melo	CEO	Sell	24,402	$2.85	$69,545.70
3/27/2013	Thani Sheikh Abdullah Bin K Al	Director	Buy	1,533,742	$3.26	$4,999,998.92
12/24/2012	Thani Sheikh Abdullah Bin K Al	Director	Buy	3,355,704	$2.98	$9,999,997.92
8/31/2012	John Melo	CEO	Sell	668,730	$3.70	$2,474,301.00
8/31/2012	L John Doerr	Director	Buy	270,270	$3.70	$999,999.00

(Data available from 1/1/2013 forward)

Amyris (NASDAQ AMRS) News Headlines

Source:

Date	Headline
	Financial Analysis: Pacific Ethanol (PEIX) & Amyris (AMRS) www.americanbankingnews.com - May 26 at 7:22 PM
	Amyris (AMRS) Presents At 19th Annual B. Riley FBR Investor Conference - Slideshow seekingalpha.com - May 25 at 5:53 PM
	HC Wainwright Reiterates "$15.00" Price Target for Amyris (AMRS) www.americanbankingnews.com - May 25 at 4:08 PM
	Brokerages Anticipate Amyris Inc (AMRS) Will Post Quarterly Sales of $37.53 Million www.americanbankingnews.com - May 24 at 8:59 AM
	BRIEF-Temasek Holdings Reports 8.9 Pct Stake In Amyris Inc www.reuters.com - May 23 at 5:35 PM
	Blog Exposure - Novvi and Chevron Sign Agreement to Develop and Bring to Market New Renewable Base Oil Technologies finance.yahoo.com - May 22 at 8:19 AM
	-$0.30 EPS Expected for Amyris Inc (AMRS) This Quarter www.americanbankingnews.com - May 22 at 1:16 AM
	BioDisrupt, Amyris Annual Investor Conference Provides Close-up of Technology & Strategy finance.yahoo.com - May 21 at 5:10 PM
	Amyris (AMRS) Given a $10.00 Price Target at B. Riley www.americanbankingnews.com - May 21 at 11:05 AM
	Critical Survey: Methanex (MEOH) versus Amyris Biotechnologies (AMRS) www.americanbankingnews.com - May 19 at 1:35 PM
	Analyzing Pacific Ethanol (PEIX) and Amyris Biotechnologies (AMRS) www.americanbankingnews.com - May 18 at 11:03 AM
	Amyris Sustainable Lubricants Joint Venture Company, Novvi, and Chevron Enter Agreement To Develop and Bring To Market New Renewable Base Oil Technologies finance.yahoo.com - May 18 at 8:39 AM
	B. Riley Equities Analysts Lower Earnings Estimates for Amyris Biotechnologies (AMRS) www.americanbankingnews.com - May 18 at 8:14 AM
	Amyris Biotechnologies (AMRS) to Post Q4 2018 Earnings of $0.23 Per Share, B. Riley Forecasts www.americanbankingnews.com - May 17 at 8:21 AM
	Comparing Gevo (GEVO) and Amyris Biotechnologies (AMRS) www.americanbankingnews.com - May 15 at 9:07 PM
	Amyris Biotechnologies (AMRS) Given a $15.00 Price Target by HC Wainwright Analysts www.americanbankingnews.com - May 15 at 2:25 PM
	Amyris Biotechnologies (AMRS) Posts Earnings Results, Misses Expectations By $1.31 EPS www.americanbankingnews.com - May 15 at 8:28 AM
	Edited Transcript of AMRS earnings conference call or presentation 14-May-18 8:30pm GMT finance.yahoo.com - May 15 at 8:26 AM
	Amyris Continues Strong Momentum and Execution with 77% Revenue Growth and Exceeds Gross Margin Target finance.yahoo.com - May 14 at 5:21 PM
	Amyris Biotechnologies (AMRS) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - May 12 at 1:15 AM
	Amyris Biotechnologies (AMRS) Downgraded to Buy at BidaskClub www.americanbankingnews.com - May 11 at 9:16 PM
	Contrasting Amyris Biotechnologies (AMRS) and Methanex (MEOH) www.americanbankingnews.com - May 11 at 7:35 PM
	Amyris to Participate in Upcoming Investor Conferences finance.yahoo.com - May 10 at 5:57 PM
	Investors Buy High Volume of Call Options on Amyris Biotechnologies (AMRS) www.americanbankingnews.com - May 10 at 7:36 AM
	Amyris Presents Its No Compromise™ Product Portfolio at Techonomy New York finance.yahoo.com - May 9 at 5:34 PM
	Insider Selling: Amyris Biotechnologies (AMRS) Major Shareholder Sells 95,162 Shares of Stock www.americanbankingnews.com - May 9 at 10:12 AM
	Future Outlook Of The Energy Industry And Amyris Inc (NASDAQ:AMRS) finance.yahoo.com - May 8 at 5:39 PM
	This Biotech Stock is Up 80% in 2018, but Is Its Business Model Sound? finance.yahoo.com - May 8 at 8:16 AM
	Amyris Biotechnologies (AMRS) Upgraded to "Buy" by ValuEngine www.americanbankingnews.com - May 7 at 11:10 PM
	Amyris Biotechnologies (AMRS) to Release Earnings on Monday www.americanbankingnews.com - May 7 at 3:46 AM
	Analysts Anticipate Amyris Biotechnologies (AMRS) Will Announce Quarterly Sales of $24.12 Million www.americanbankingnews.com - May 6 at 2:40 AM
	Amyris Biotechnologies (AMRS) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - May 5 at 1:06 AM
	Amyris Collaborates with Firmenich to Develop Disruptive Bio-Based Fragrance Ingredient finance.yahoo.com - May 3 at 5:25 PM
	Amyris Biotechnologies (AMRS) Cut to "Hold" at Zacks Investment Research www.americanbankingnews.com - May 3 at 4:24 PM
	Amyris Biotechnologies (AMRS) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - May 2 at 4:52 PM
	Amyris Biotechnologies (AMRS) & Its Rivals Critical Contrast www.americanbankingnews.com - May 1 at 8:48 AM
	Comparing Amyris Biotechnologies (AMRS) & The Competition www.americanbankingnews.com - April 30 at 3:20 AM
	Amyris Biotechnologies (AMRS) and The Competition Head to Head Survey www.americanbankingnews.com - April 28 at 9:16 PM
	Head-To-Head Contrast: Amyris Biotechnologies (AMRS) and Its Peers www.americanbankingnews.com - April 28 at 9:25 AM
	Comparing Amyris Biotechnologies (AMRS) and Its Rivals www.americanbankingnews.com - April 27 at 5:20 PM
	Amyris Biotechnologies (AMRS) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - April 26 at 4:22 PM
	Amyris Biotechnologies (AMRS) & Its Competitors Head-To-Head Analysis www.americanbankingnews.com - April 26 at 3:13 PM
	Amyris Biotechnologies (AMRS) Raised to "Buy" at Zacks Investment Research www.americanbankingnews.com - April 25 at 4:04 PM
	Head to Head Review: Amyris Biotechnologies (AMRS) & Its Rivals www.americanbankingnews.com - April 24 at 11:18 AM
	Critical Contrast: Amyris Biotechnologies (AMRS) vs. The Competition www.americanbankingnews.com - April 24 at 9:22 AM
	Amyris sees a future beyond fuels www.bizjournals.com - April 20 at 8:23 AM
	Analysts Expect Amyris Inc (AMRS) Will Post Quarterly Sales of $24.12 Million www.americanbankingnews.com - April 19 at 2:50 AM
	Amyris (AMRS) vs. Its Peers Financial Contrast www.americanbankingnews.com - April 18 at 9:14 PM
	Reviewing Amyris (AMRS) and Its Peers www.americanbankingnews.com - April 18 at 9:31 AM
	Stock Review for Specialty Chemicals Investors -- Aemetis, Amyris, Axalta Coating Systems, and Delta Technology www.prnewswire.com - April 18 at 8:16 AM

Amyris (NASDAQ:AMRS) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Amyris (NASDAQ:AMRS) Income Statement, Balance Sheet and Cash Flow Statement

Amyris (NASDAQ AMRS) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff